At a glance
A multicomponent preparation investigated in neurological research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Human and preclinical studies examine neurological outcomes in different conditions. A research-vial mass cannot automatically be substituted for the volume and composition of a clinical preparation.[4][5][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Cerebrolysin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 60 mg · 1 source tables
Standard / Gradual Approach (3 mL = 20 mg/mL)
| Week | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Week 1 | 20 mg (20,000 mcg) | 100 units (1.0 mL) × 1 |
| Week 2 | 24 mg (24,000 mcg) | 60 units (0.6 mL) AM + 60 units (0.6 mL) PM |
| Week 3 | 28 mg (28,000 mcg) | 70 units (0.7 mL) AM + 70 units (0.7 mL) PM |
| Week 4+ | 32 mg (32,000 mcg) | 80 units (0.8 mL) AM + 80 units (0.8 mL) PM |
Frequency: Inject once or twice daily subcutaneously as shown above. Doses exceeding 100 units (1.0 mL) should be split into AM and PM administrations. Clinical literature describes daily doses ranging from 215 mg (1 mL of commercial solution) up to higher IV infusions[1]; this protocol uses a conservative subcutaneous approach with gradual titration.
Additional schedule context & duration
Concise summary of the daily regimen.
- Goal: Support neuroprotection and neuronal survival through neurotrophic factor mimicry[1][2].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 20–32 mg daily with gradual titration.
- Reconstitution: 3.0 mL per 60 mg vial (20 mg/mL) for accurate unit measurements.
- Storage: Lyophilized at room temperature (≤25 °C); reconstituted refrigerated (2–8 °C); do not freeze.
Suggested daily titration approach.
- Start: 20 mg daily (100 units); increase by ~4 mg (20 units) per week as tolerated.
- Target: 28–32 mg daily by Weeks 3–4.
- Frequency: Once or twice per day (subcutaneous); split doses >20 mg into AM/PM.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time(s); rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 7 days[8].
Storage Instructions
Proper storage preserves peptide quality.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[6][7].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a 2–4 cm skinfold; insert the needle at 45–90° into subcutaneous tissue[6].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[7].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[9].
- For split‑dose protocols (AM/PM), use different injection sites for each administration.
Materials & quantity planning
Source materials checklist · 60 mg
Plan based on an 8–16 week daily protocol with gradual titration. At maintenance dose (~32 mg/day), each 60 mg vial provides approximately 1.9 doses.
-
Peptide Vials (Cerebrolysin, 60 mg each):
- 8 weeks ≈ 26 vials
- 12 weeks ≈ 42 vials
- 16 weeks ≈ 58 vials
-
Insulin Syringes (U‑100): Count based on injections per day (1–2 depending on dose).
- Week 1 (1/day): 7 syringes
- Weeks 2–8 (2/day): 98 syringes
- 8 weeks total: 105 syringes
- 12 weeks total: 161 syringes
- 16 weeks total: 217 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (26 vials): 78 mL → 8 × 10 mL bottles
- 12 weeks (42 vials): 126 mL → 13 × 10 mL bottles
- 16 weeks (58 vials): 174 mL → 18 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- 8 weeks (105 injections): 210 swabs → recommend 3 × 100‑count boxes
- 12 weeks (161 injections): 322 swabs → recommend 4 × 100‑count boxes
- 16 weeks (217 injections): 434 swabs → recommend 5 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 60 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Research publication
Zhang et al., Med Sci Monit (PMC) — Meta‑analysis of Cerebrolysin efficacy and safety in acute ischemic stroke (2017) (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
Espinoza et al., Behav Brain Res (PubMed) — Cerebrolysin neuroprotection and neurorepair in diabetic rat model (2024) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Public health resource
CDC — Injection safety: preventing unsafe injection practices in clinical settings (2024) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
- 09
Public health resource
NCBI Bookshelf — Subcutaneous injection technique: preparation, administration, and site rotation (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Research publication
Subcutaneous Drug Delivery Review (PMC) — Pharmacologic considerations and best practices for subcutaneous administration (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
Cognitive Frailty & Cerebrolysin Review (PMC) — Evidence for peptidergic nootropics in age‑related cognitive decline (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Research publication
Neurotrophic Factors & Neurodegeneration (PMC) — Role of NGF/BDNF pathways in neuroprotection and neuroplasticity (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.